Antibacterial therapy with bacteriophage genotypically modified

Details Antibacterial therapy with bacteriophage genotypically modified Antibacterial therapy with bacteriophage genotypically modified

1995-06-05

1997-08-26

Guzo, David

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Testing efficacy or toxicity of a compound or composition

435 5, 4352351, 435236, 435237, A61K 4900, C12N 702, C12N 708, C12Q 170

Patent

active

056608128

ABSTRACT:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.

REFERENCES:
Merril et al., Long-circulating bacteriophage as antibacterial agents. PNAS (USA) vol. 93:3188-3192. Apr. 1996.
Perham et al., Engineering a peptide epitope display system on filamentous bacteriophage. FEMS Microbiol. Revs. vol. 17:25-31. Jan. 1995.

Affiliated with

Also associated with

Rating

Antibacterial therapy with bacteriophage genotypically modified does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibacterial therapy with bacteriophage genotypically modified , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial therapy with bacteriophage genotypically modified will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1986275